Viewing data from:

TECHNIVIE

NDA

OMBITASVIR; PARITAPREVIR; RITONAVIR | N207931 | ABBVIE INC

1 strength6 unique patents0 unique exclusivities

Patent Timeline

6 unique patents by expiration date

Active (6)TodayPED (+6 mo)

2027

2028

2029

2030

2031

2032

Today

Oct. 10, 2031

Sep. 10, 2029

Jun. 9, 2031

Apr. 13, 2032

Jun. 10, 2030

Apr. 10, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

10 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

6 patents0 exclusivities▴

TABLET;ORAL | Approved: Jul 24, 2015

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8420596	Apr 10, 2031PED: Oct 10, 2031	PED	Yes	Yes	—	—
8642538	Sep 10, 2029	—	Yes	Yes		—
8686026	Jun 9, 2031	—	—	Yes	—	—
8691938	Apr 13, 2032	—	Yes	Yes	—	—
9006387	Jun 10, 2030	—	—	—		—
9044480	Apr 10, 2031	—	—	—		—